Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

The heterogeneity of therapeutic modalities and eligibility criteria and the lack of long-term follow-up in most reports of neoadjuvant chemotherapy for breast cancer preclude us from drawing conclusions about its value in clinically relevant patient subgroups. The present study aims to identify pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Brain, E., Garrino, C., Misset, J. L., Carbonero, I. G., Itzhaki, M., Cvitkovic, E., Goldschmidt, E., Burki, F., Regensberg, C., Pappo, E., Hagipantelli, R., Musset, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228243/
https://www.ncbi.nlm.nih.gov/pubmed/9155059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228243/
https://www.ncbi.nlm.nih.gov/pubmed/9155059

Ejemplares similares